Helle Linnebjerg

2.3k total citations · 2 hit papers
60 papers, 1.7k citations indexed

About

Helle Linnebjerg is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Helle Linnebjerg has authored 60 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Endocrinology, Diabetes and Metabolism, 31 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in Helle Linnebjerg's work include Diabetes Treatment and Management (39 papers), Diabetes Management and Research (36 papers) and Pancreatic function and diabetes (27 papers). Helle Linnebjerg is often cited by papers focused on Diabetes Treatment and Management (39 papers), Diabetes Management and Research (36 papers) and Pancreatic function and diabetes (27 papers). Helle Linnebjerg collaborates with scholars based in United States, Singapore and United Kingdom. Helle Linnebjerg's co-authors include Kenneth Mace, Prajakti A. Kothare, Soomin Park, Michael Trautmann, Malcolm I. Mitchell, Mary Seger, Shobha Reddy, Mark Fineman, David E. Coutant and Danny Soon and has published in prestigious journals such as JAMA, Journal of the American College of Cardiology and Diabetes Care.

In The Last Decade

Helle Linnebjerg

57 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)

2023 124 citations Steven E. Nissen, Helle Linnebjerg et al. JAMA profile →
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation

2023 112 citations Stephen J. Nicholls, Steven E. Nissen et al. JAMA profile →

Peers

Helle Linnebjerg

EDM

SURGE

PHARM

GENET

Kenneth Mace United States

Masashi Shimoda Japan

Akinobu Nakamura Japan

Maria Gerasimova United States

P. Damsbo Denmark

Mehmood Khan United States

Mario Maioli Italy

D Pometta Switzerland

Carolina Solis‐Herrera United States

A. Rees United Kingdom

Kenneth Mace United States

Helle Linnebjerg

1.0k ×0.8

EDM

635 ×0.7

SURGE

461 ×1.1

219 ×1.1

PHARM

55 ×0.3

GENET

Citations per year, relative to Helle Linnebjerg Helle Linnebjerg (= 1×) peers Kenneth Mace

Countries citing papers authored by Helle Linnebjerg

Since Specialization

Citations

This map shows the geographic impact of Helle Linnebjerg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helle Linnebjerg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helle Linnebjerg more than expected).

Fields of papers citing papers by Helle Linnebjerg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helle Linnebjerg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helle Linnebjerg. The network helps show where Helle Linnebjerg may publish in the future.

Co-authorship network of co-authors of Helle Linnebjerg

This figure shows the co-authorship network connecting the top 25 collaborators of Helle Linnebjerg. A scholar is included among the top collaborators of Helle Linnebjerg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helle Linnebjerg. Helle Linnebjerg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aronson, Ronnie, Torben Biester, Jennifer Leohr, et al.. (2023). Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 25(7). 1964–1972. 3 indexed citations

Nicholls, Stephen J., Steven E. Nissen, Cynthia Griggs Fleming, et al.. (2023). Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation. JAMA. 330(11). 1042–1042. 112 indexed citations breakdown →

Leohr, Jennifer, et al.. (2021). Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data. Clinical Pharmacokinetics. 60(11). 1423–1434. 19 indexed citations

Leohr, Jennifer, Mary Anne Dellva, Elizabeth LaBell, et al.. (2020). Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. Clinical Therapeutics. 42(9). 1762–1777.e4. 15 indexed citations

Heise, Tim, Helle Linnebjerg, David E. Coutant, et al.. (2020). Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obesity and Metabolism. 22(10). 1789–1798. 47 indexed citations

Linnebjerg, Helle, Qianyi Zhang, Elizabeth LaBell, et al.. (2020). Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial. Clinical Pharmacokinetics. 59(12). 1589–1599. 45 indexed citations

Linnebjerg, Helle, Elizabeth LaBell, Mary Anne Dellva, David E. Coutant, & Jennifer Leohr. (2020). Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects. Diabetes Therapy. 11(8). 1709–1720. 4 indexed citations

Leohr, Jennifer, Mary Anne Dellva, David E. Coutant, et al.. (2020). Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clinical Pharmacokinetics. 59(12). 1601–1610. 26 indexed citations

Pörksen, Niels, Helle Linnebjerg, Parag Garhyan, et al.. (2018). Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 20(5). 1193–1201. 5 indexed citations

10.

Søndergaard, Esben, Helle Linnebjerg, Parag Garhyan, et al.. (2017). Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes. Diabetes Obesity and Metabolism. 20(2). 419–426. 7 indexed citations

11.

Peña, Amparo de la, Mary Seger, Danny Soon, et al.. (2015). Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clinical Pharmacology in Drug Development. 5(1). 69–75. 42 indexed citations

12.

Keller, Jutta, Michael Trautmann, Harry Haber, et al.. (2012). Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regulatory Peptides. 179(1-3). 77–83. 52 indexed citations

13.

Linnebjerg, Helle, et al.. (2009). The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. International Journal of Clinical Pharmacology and Therapeutics. 47(11). 651–658. 12 indexed citations

14.

Linnebjerg, Helle, Soomin Park, Prajakti A. Kothare, et al.. (2008). Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regulatory Peptides. 151(1-3). 123–129. 207 indexed citations

15.

Zhao, Xia, Yuan Cui, Yanling Zhou, et al.. (2008). Exenatide pharmacokinetics in healthy Chinese subjects. International Journal of Clinical Pharmacology and Therapeutics. 46(9). 459–465. 7 indexed citations

16.

Linnebjerg, Helle, Prajakti A. Kothare, Soomin Park, et al.. (2007). Effect of renal impairment on the pharmacokinetics of exenatide. British Journal of Clinical Pharmacology. 64(3). 317–327. 142 indexed citations

17.

Soon, Danny, Prajakti A. Kothare, Helle Linnebjerg, et al.. (2006). Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men. The Journal of Clinical Pharmacology. 46(10). 1179–1187. 48 indexed citations

18.

Kothare, Prajakti A., Danny Soon, Helle Linnebjerg, et al.. (2005). Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin. The Journal of Clinical Pharmacology. 45(9). 1032–1037. 53 indexed citations

19.

Linnebjerg, Helle, et al.. (1995). THE EFFECT OF DIETARY POLYUNSATURATED FATTY ACIDS (PUFA) ON ACUTE REJECTION AND CARDIAC ALLOGRAFT BLOOD FLOW IN RATS. Transplantation. 60(6). 570–576. 1 indexed citations

20.

Linnebjerg, Helle, Harald S. Hansen, & Benny Jensen. (1989). Effect of amiloride on arachidonic acid and histamine release from rat mast cells. Inflammation Research. 27(1-2). 39–42. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact